ClinicalTrials.gg
CompletedNCT00350792Updated Oct 13, 2010Results posted

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

A Phase 2 interventional study of pemetrexed and carboplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2010-10-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
114th of 223
62 · median 64
Started
2006
with 24 others
Phase 2
128 of 227
12 open now
Registered
37th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 114th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 37th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV
  • No previous chemotherapy for lung cancer
  • Men and women > or = 70 years
  • At least one uni-dimensionally ( [RECIST]criteria)
  • (ECOG) Performance Status 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Treatment within the last 30 days with a drug that has not received regulatory approval
  • Serious systemic disorders
  • Inability to discontinue administration of aspirin or anti-inflammatory non
  • Concurrent administration of any other antitumor therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Carboplatin

    Pemetrexed: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles. Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles.

    Drug: pemetrexed · Drug: carboplatin

Interventions

  • 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles

    Also known as: LY231514, Alimta

  • Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)

    Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.

    Time frame: baseline to measured objective tumor response (up to six 21-day cycles)

Secondary outcomes

  1. Time to Treatment Failure

    Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

    Time frame: baseline to stopping treatment (up to six 21-day cycles)

  2. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline to date of death from any cause (up to 14.5 months)

  3. Estimated Probability of One Year Progression-free Survival

    Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.

    Time frame: baseline to measured progressive disease or death, 1 year

Other outcomes

  1. Time to Treatment Failure

    Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

    Time frame: baseline to stopping treatment (up to six 21-day cycles)

07

Results

Posted Dec 9, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Carboplatin
Started62
Completed29
Not completed33
Withdrew: Adverse event11
Withdrew: Death from study disease1
Withdrew: Death from study drug toxicity1
Withdrew: Death not study drug related2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject4
Withdrew: Physician decision2
Withdrew: Lack of efficacy11

Outcome measures

PrimaryPercentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)

Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.

Time frame:
baseline to measured objective tumor response (up to six 21-day cycles)
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)
percentage of participantsPemetrexed + Carboplatin
Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)28.6 (16.58 to 43.26)
Other pre-specifiedTime to Treatment Failure

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

Time frame:
baseline to stopping treatment (up to six 21-day cycles)
Reported as:
Mean · weeks
Time to Treatment Failure
weeksPemetrexed + Carboplatin
Time to Treatment Failure12.95 ± 0.74
SecondaryTime to Treatment Failure

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

Time frame:
baseline to stopping treatment (up to six 21-day cycles)
Reported as:
Median · weeks
Time to Treatment Failure
weeksPemetrexed + Carboplatin
Time to Treatment Failure16.0 (10.1 to NA)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline to date of death from any cause (up to 14.5 months)
Reported as:
Median · months
Overall Survival
monthsPemetrexed + Carboplatin
Overall Survival10.4 (9.1 to 12.9)
SecondaryEstimated Probability of One Year Progression-free Survival

Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.

Time frame:
baseline to measured progressive disease or death, 1 year
Reported as:
Median · percentage of patients
Estimated Probability of One Year Progression-free Survival
percentage of patientsPemetrexed + Carboplatin
Estimated Probability of One Year Progression-free Survival13.1 (4.6 to 21.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Carboplatin—26/62 (41.9%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPemetrexed + Carboplatin
DyspnoeaRespiratory, thoracic and mediastinal disorders6/62
AnaemiaBlood and lymphatic system disorders4/62
ThrombocytopeniaBlood and lymphatic system disorders4/62
General physical health deteriorationGeneral disorders4/62
NeutropeniaBlood and lymphatic system disorders3/62
DiarrhoeaGastrointestinal disorders3/62
SepsisInfections and infestations2/62
Bone marrow failureBlood and lymphatic system disorders1/62
Febrile bone marrow aplasiaBlood and lymphatic system disorders1/62
Febrile neutropeniaBlood and lymphatic system disorders1/62
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPemetrexed + Carboplatin
NeutropeniaBlood and lymphatic system disorders44/62
AstheniaGeneral disorders42/62
AnaemiaBlood and lymphatic system disorders35/62
ThrombocytopeniaBlood and lymphatic system disorders29/62
AnorexiaMetabolism and nutrition disorders25/62
Weight decreasedInvestigations23/62
ConstipationGastrointestinal disorders21/62
NauseaGastrointestinal disorders21/62
VomitingGastrointestinal disorders14/62
LeukopeniaBlood and lymphatic system disorders12/62

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Carboplatin
Mean76.5 ± 3.6
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Carboplatin
Female11
Male51
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Carboplatin
France62
Disease Stage
Disease Stage(participants)Pemetrexed + Carboplatin
Stage IIIB13
Stage IV49
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed + Carboplatin
0 - Fully Active10
1 - Ambulatory, Restricted Strenuous Activity52
Pathological Diagnosis
Pathological Diagnosis(participants)Pemetrexed + Carboplatin
Large Cell Lung Cancer5
Adenocarcinoma of Lung32
Squamous Cell Carcinoma of Lung21
Other: Carcinoma-Infiltrant Indifferencie1
Other: Carcinoma1
Other: Indifferencied Non-Small Cell Lung Cancer1
Other: Undifferentiated1
08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bobigny, 93009, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brest, 29609, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caen, 14076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Le Mans, 72000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44202, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre Les Nancy, 54511, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Nov 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2006
First posted
Jul 11, 2006
Start
Aug 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2009
Results first posted
Dec 9, 2009
Last update
Oct 13, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00350792
First posted
Jul 11, 2006
Start date
Aug 2006
Primary completion
Nov 2008
Completion
Nov 2009
Results posted
Dec 9, 2009
Last update
Oct 13, 2010

Study contacts

1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Carboplatin

Start the discussion